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Abstract
Human liver is enriched with CD8CT- and CD3CCD56C natural T (NT)-lymphocytes, important anti-tumour effectors, similar
to murine NKTs. IL-12 promotes anti-tumour functions of NKTs. We quantified IL-12 and CD56C/CD8CT lymphocytes in
normal and tumour bearing liver. We also examined the effect of IL-12 on the expansion/activation of peripheral blood cells in vitro.
IL-12 was detected in normal (n ¼ 13, median 2032 pg/100 mg protein) and increased in tumour bearing liver (n ¼ 9, 3678 pg,
p! 0:01). Infiltrating monocytes appear to be the principal producers. Culture with IL-12 selectively expanded CD8CT and
CD3CCD56CNT cells and polarised their cytokine responses to Th1-type. However, there was no in vivo expansion of these cells
in tumour bearing liver. Changes observed in culture required addition of IL-2.We therefore quantified IL-2 in hepatic tissue. IL-2 was
detected in normal liver (median 4700 pg/100 mg protein). Surprisingly, there was no increase in tumour-infiltrated liver (4910 pg).
The presence of IL-12 may create an environment in healthy liver that promotes the accumulation of CD8CT and CD56CNT cells.
Therefore, the development of metastases in the presence of high levels of IL-12 may be due to an insufficient IL-12 response.
Alternatively, lack of IL-2 rather than a defect in IL-12, may be responsible for insufficient expansion/activation of tumour specific
cytotoxic T lymphocytes.
 2004 Elsevier Ltd. All rights reserved.
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The adult human liver is constantly exposed to a large
antigenic load which includes pathogens, toxins and
tumour cells. Because of its location and rich blood
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doi:10.1016/j.cyto.2003.11.012supply, it is the primary site of metastases from
colorectal carcinoma [1]. It is not surprising therefore
that in addition to classical CD8C cytotoxic T
lymphocytes of the adaptive immune system, the liver
is a particularly rich source of lymphocytes that have
a critical role in the early innate immune response
against malignancy. These cellsdnatural killer (NK)
cells (CD3CD56C) and natural T (NT) cells
(CD3CCD56C) account for greater than 50% of the
hepatic lymphocyte pool, compared to approximately
15% in the peripheral blood [2e4]. NK cells in vivo
spontaneously kill MHC class I deficient tumour cells
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and produce cytokines upon interaction of their cell
surface receptor with ligands [5,6]. Recently, tumour
immunology has been revolutionised by the discovery of
the role of NKT cells in the innate immune response to
malignancy [7e10]. Murine NKT cells, particularly
those expressing the invariant TCRa chain Va14
Ja218, have been shown to have a direct antimetastatic
role in certain inbred strains of mice [11]. Human NT
cells display several phenotypic and functional similar-
ities to murine NKT cells. They can rapidly lyse a range
of tumour cell lines in vitro, rapidly secrete both IFN-g
and IL-4, and they express NK cell stimulatory, co-
stimulatory and inhibitory receptors [12,13]. It is
therefore likely that they may have similar antimeta-
static roles to murine NKT cells. The hepatic microen-
vironment, specifically the cytokine milieu, has the
potential to influence the function of these cells [14].
Interleukin 12 is a heterodimeric cytokine composed
of two covalently linked p35 and p40 subunits, both of
which are required for biological activity. It is produced
primarily by antigen presenting cells such as monocytes,
macrophages and dendritic cells and is central to the
inflammatory response. It enhances the cytotoxic
activity of Th1 cells, NKT and NK cells and induces
the production of inflammatory cytokines including
interferon gamma (IFN-g) and tumour necrosis factor
alpha (TNF-a) [15e21]. Recently, a major antimeta-
static role has been ascribed to IL-12. It has been
shown to induce anti-tumour activity and tumour
rejection in several animal models following systemic
treatment with recombinant protein [22e25] or gene
therapy for orthotopic carcinoma models [26,27]. There
is a large body of evidence to show that the
antimetastatic effect of IL-12 in mice is mediated
through NK and NKT cells [9,11,28,29]. Mice deficient
in the Va14 T cell receptor a chain, which is expressed
by NKT cells can no longer mediate IL-12 induced
rejection of tumours [11]. Va14 cells are an essential
target of IL-12 and mediated IL-12 induced cytotoxicity
by an NK-like effector mechanism. The anti-tumour
effect of IL-12 can be replaced by the adoptive transfer
of IL-12 activated Va14 NKT cells, but not by IL-12
activated NK cells [10]. IL-12 is currently being
assessed in clinical trials for the treatment of human
malignancy [30]. However, the level of IL-12 in human
liver is not known, nor has the implications of this on
the accumulation of NT cell populations in malignant
liver been studied. The aim of this study was to
determine IL-12 protein levels in normal liver and, to
compare this to levels in tumour infiltrated human
hepatic tissue, analysed ex vivo in the absence of
stimulation. We also investigated the effects of IL-12 on
human T lymphocyte subpopulation expansion in vitro
and quantified these subpopulations in normal and
tumour bearing human liver.2. Results
2.1. IL-12 protein levels in normal and tumour liver
Soluble protein was extracted from 13 normal and 9
tumour samples and yield was estimated using the BCA
protein assay. Mean protein yield per 100 mg liver tissue
powder was 8.1 mg (range 2.6e17.5). All samples tested
positive for IL-12 protein. IL-12 was detected in normal
liver, in the absence of in vitro stimulation at a median
concentration of 2032 pg/100 mg protein. Similar levels
were present in stimulated PBMCs (median 1981 pg/
100 mg protein). Significantly lower levels were detected
in resting PBMCs (1012 pg/100 mg protein, p! 0:05).
IL-12 in tumour-infiltrated liver was significantly raised
compared to normal liver (median 3678 pg/100 mg
protein, p! 0:01) (Fig. 1).
2.2. Localisation of IL-12 producing cells
in hepatic tissue
Immunohistochemical staining of hepatic tissue
showed that IL-12 protein was mainly distributed within
portal tracts. The cells staining positively for IL-12 have
a mononuclear morphology and are therefore likely to
be infiltrating monocytes (Fig. 2).
2.3. Effect of IL-2 and IL-12 on expansion
of PBMCs
Following stimulation of PBMCs with anti-CD3 and
21 day culture with medium alone, IL-2 or a combina-
tion of IL-2 and IL-12, the cells were phenotypically
characterised by surface mAb staining and three colour
flow cytometry. The combination of IL-2 and IL-12
resulted in the selective expansion of CD8CT cells.
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Fig. 1. Levels of IL-12 in normal and tumour bearing liver. IL-12 is
significantly increased in tumour bearing liver. Levels in normal liver
are similar to those of stimulated PBMCs, which are significantly
greater than resting PBMCs. Each data point represents an individual
sample. Horizontal bars represent the median.
275A.M. Kelly et al. / Cytokine 25 (2004) 273e282Fig. 2. Localisation of IL-12 expressing cells in hepatic tissue. (A) Staining pattern in normal tissue. IL-12 was mainly distributed within portal tracts.
(B) Increased levels of IL-12 in tumour bearing liver may be a reflection of an increased inflammatory infiltrate within the portal tract. (C) Normal
liver at a higher magnification shows the cells staining positively for IL-12 have a mononuclear morphology and are therefore likely to be infiltrating
monocytes. (D) IgG negative control.These cells were expanded from a median value of
26.9% of total lymphocytes to 56.6% following culture
with IL-2 and IL-12. A greater than twofold expansion
of NT cells (CD3CCD56C) was also observed follow-
ing culture with IL-2 and IL-12 in combination
(4.18%e11.06%). There were no expansions of either
of these cell types following culture with IL-2 alone.
CD4CT cells expanded from a median value of 47.8%
on day 0 to 51.7% following culture with IL-2 in
combination with IL-12. This contrasts with an expan-
sion to 75.3% following culture with IL-2 alone.
CD4CCD8C cells expanded from a median value of
0.87% of total lymphocytes prior to culture to a median
of 1.89% following culture with IL-2 and to 6.2%
following culture with IL-2 and IL-12 in combination
(Figs. 3 and 4). Stimulated cells cultured in IL-12 alone
were not viable following 21 day culture.2.4. Effect of IL-2 and IL-12 on expansion
of NT cell subsets
The CD3CCD56CNT cells that expanded following
culture with IL-2 and IL-12 in combination were further
characterised. CD4CNT cells expanded from a mean of
1.3% of all NT cells prior to culture to a mean of 75%
following culture with IL-2 and IL-12. Prior to culture
54.6% of all NT cells were CD8C, however following
culture they represented only 28% of all NT cells.
Almost 60% of all NTs were abTCRC and 36% were
gdTCRC prior to culture but following culture this had
changed to 94% and 3.5%, respectively. CD57C NT
cells were also depleted on culture, with 38% of NT cells
expressing this marker prior to culture but only 6.4%
following culture. Similarly the expression of CD161
was reduced from 26% prior to culture to 3% following
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Fig. 3. Cell surface phenotype was examined by flow cytometry, prior to (B) and following 21 day culture with IL-2 (6) or IL-2 in combination with
IL-12 (,). CD3CCD8C and CD3CCD56C cells were significantly expanded by addition of IL-12. Conversely, addition of IL-12 inhibits IL-2
mediated expansion of CD3CCD4C cells.culture. This depletion of CD161 and CD57 is likely
a reflection of the loss of activated cells pre-programmed
for apoptosis. Forty-five percent of all NT cells ex-
pressed CD94 prior to culture and this remains largely
unchanged at 42% following culture. In order to
determine if these changes were attributable to IL-12,
we also examined the effect of culture with IL-2 in the
absence of IL-12. Culture with IL-2 alone resulted in
similar changes as those described for IL-2 in combina-
tion with IL-12 (Table 1).
2.5. Effect of IL-12 on cytokine secretion by NT
and T cells
The effect of IL-2 and IL-12 on cytokine production by
NT cells and conventionalCD56Tcells after stimulation
with plate-bound anti-CD3 mAb was tested by flow
cytometry. Fig. 5 shows that the Th1 cytokine, IFN-gwas
produced by a third of NT cells (median 32.98%)
following culture with IL-12 alone. This is in contrast to
IFN-g production by 14.8% of NT cells cultured in
medium alone. Culturing in a combination of IL-2 and
IL-12 resulted in IFN-g production by themajority ofNT
cells (median 57.5%). However, a similar effect was seen
following culture with IL-2 alone (median 62.6%). In
contrast, IL-12 did not promote IFN-g production by
conventional T cells. Secretion of the Th2 cytokine IL-4
was not enhanced by culture with IL-12.
2.6. Levels of CD8C and CD56C T cells
in normal and tumour liver
Using flow cytometry, we estimated the percentages of
hepatic lymphocytes expressing CD8 and CD56 innormal and tumour bearing liver. Two thirds of hepatic
T cells from normal donor liver were CD8C (median
66.7%, range59.5e75.6%).Surprisingly, these levelswere
not increased in tumour bearing liver (median 67.5%,
range 46.1e90.2%). Similarly, there was no significant
difference in the level of hepatic T cells co-expressing
CD56 in tumour bearing compared to normal liver
(median 19.7% in tumour, 21.4% in normal) (Fig. 6).
2.7. IL-2 protein levels in normal and tumour liver
As the changes observed in cell culture appear to be
related to contact with IL-2, we determined the ex vivo
level of IL-2 in liver tissue. Soluble protein was extracted
from five normal and five tumour samples and yield was
estimated using the BCA protein assay. All samples
tested positive for IL-2 protein. IL-2 was detected in
normal liver, in the absence of in vitro stimulation at
a median concentration of 4700 pg/100 mg protein
(range 4490e12160). Surprisingly, there was no signif-
icant increase in levels of IL-2 in tumour-infiltrated liver
(4910 pg/100 mg protein, range 2240e8390).
3. Discussion
The human liver is emerging as an important site of
anti-tumour immunity and its lymphocyte repertoire
represents a significant part of this defence mechanism.
The hepatic lymphocyte environment is a particularly
rich source of NK and NT cells, key mediators of anti-
tumour immunity [3,4,31e34]. The factors that influence
the accumulation of NK and NT cells are likely to
277A.M. Kelly et al. / Cytokine 25 (2004) 273e282Fig. 4. Representative flow cytometric profiles. The top panel shows CD3CCD4C cells prior to culture (A), following culture with IL-2 (B) and with
IL-2 and IL-12 (C). The middle and lower panels show the same plots for CD3CCD8C (DeF) and CD3CCD56C (GeI), respectively.include adhesion molecules, chemokines and cytokines
[35]. IL-12 is a critical cytokine in anti-tumour immunity
[17,22e29], but a quantitative difference in levels in
normal and tumour bearing liver has not previously
been demonstrated. In the present study, we quantified
IL-12 levels and localised its expression in normal and
tumour bearing liver samples and investigated the effects
of this cytokine on proliferation and cytokine pro-
duction by NT cells. Using ELISA, we found significant
IL-12 levels in homogenised liver tissue from organ
donors. These levels were comparable to those produced
by in vitro stimulated PBMCs, suggesting the presence
of an inflammatory microenvironment in the healthy
liver. IL-12 levels were significantly higher in liver
samples from patients with hepatic malignancy, suggest-
ing activation of expression of this cytokine and its
possible role in the regulation of the anti-tumour
response. Using immunohistochemistry, we have dem-
onstrated that IL-12 producing cells were confined to
portal tracts and thus are likely to be infiltrating
monocytes. Surprisingly, there was no evidence of
a sinusoidal distribution suggesting that hepatic kupffer
cells are not the major producers of hepatic IL-12.Added in vitro to PBMCs, stimulated by antibody
crosslinking of CD3, IL-12 alone did not induce
expansions of any lymphocyte subsets. In the presence
of IL-2, however, IL-12 induced the selective expansion of
CD8CT cells, CD3CCD56CNT cells and double positive
CD4CCD8CT cells. These T cell populations were not
expanded by IL-2 alone. Thus, IL-12 in the presence of
IL-2 appears to support expansions of inflammatory
lymphocytes, known to be capable of cytotoxic function.
Table 1
Characterisation of NT (CD3CCD56C) sub-populations following
culture with IL-2 compared with IL-2 in combination with IL-12
Pre-culture Post-culture
Medium IL-2 IL-2 and IL-12
CD4C 3.5 (0.13e24) 67.0 (2.5e85) 65.5 (36e85.7)
CD8C 56.5 (37e70) 44.0 (14.8e67) 29.5 (19.5e69)
abTCR 67.5 (36.4e99) 90.5 (93e100) 98.0 (97.5e100)
gdTCR 35.0 (9.6e63.6) 5.2 (0e11.6) 3.4 (0e7.2)
CD94C 41.9 (23e50) 39.0 (14.3e60.9) 44.2 (30e49.3)
CD57C 27.0 (18.2e57) 0 (0e20.4) 0.75 (0e3.7)
CD161C 47.1 (18.5e70) 0 (0e3.5) 0.40 (0e5.5)
All experiments were performed on six separate samples and results are
presented as median (range) of values.
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with blood suggest a role for this cytokine in the
accumulation of CD8CT cells and NT cells in the liver.
Themajority of human hepatic andperipheralNT cells
express CD8. In order to investigate whether the observed
expansion of CD8CT cells was due to the expansion of
NT cells, we further characterised the phenotypes of the
expandedNT cells. In contrast to the overall expansion of
CD8CT lymphocytes, within the NT cell subpopulation
CD4C cells were selectively expanded. Culture with IL-12
also resulted in the selective expansion of abNT cells with
a significant reduction in gdNT cells. This contrasts to
a previous study in which the majority of NT cells were
CD8CgdC following culture [14]. Takeda et al. [28] have
previously demonstrated that IL-12 activates liver NK1.1
CD4Cab T cells as a major effector in the inhibition of
experimental tumour metastases. It is interesting to note
that although culture with IL-2 and IL-12 significantly
expands CD3CCD56C cells when compared to IL-2
alone, the changes in the subpopulations of these NT cells
are similar following culture with IL-2 alone compared
with IL-2 and IL-12. This implies that although IL-12 is
responsible for the expansion of NT cells, it does not
contribute to the changes in phenotype. Recently, Dunne
et al. [35] reported that in the absence of stimulation,
culture of PBMCs with IL-2 resulted in the selective
expansion ofNT cells, althoughCD4, CD8 ab and gdNT
cells were similarly expanded. Our results indicate that
upon stimulation, NT cells do not selectively expand
among PBMCs in response to IL-2 alone, but CD4T cells
do. Therefore, this would suggest that the combined
effects of TCR stimulation and cytokine induction are
different than the effects of either treatment alone.
IL-12 released by macrophages and dendritic cells
polarises CD4CT cell differentiation to Th1 cells,
producing IFN-g but not IL-4 [15]. In contrast to
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Fig. 5. IFN-g secretion by NT cells and T cells cultured in medium
alone, IL-2, IL-12 and IL-2 in combination with IL-12 for 72 h and
subsequently stimulated with anti-CD3 in the presence of Brefeldin A
for 4 h. Results are expressed as the median percentage of each cell
type showing positive intracytoplasmic staining for IFN-g and
represent five experiments.conventional T cells, NT cells appear to be terminally
differentiated, exhibiting effector functions within hours
of activation. NT cells are uniquely capable of pro-
ducing both IFN-g and IL-4, therefore we investigated
the effects of IL-2 and IL-12 on the production of these
cytokines by NT cells after stimulation for 4 h by CD3
crosslinking. Our results confirm that NT cells, but not
CD56T cells, can be activated to produce cytokines
within 4 h. Preincubation with either IL-2, IL-12, or
a combination of IL-2 and IL-12 led to an enhancement
of rapid IFN-g production by NT cells but not of IL-4
production. It is likely that culture with IL-2 alone
results in maximal stimulation of these cells, therefore,
no additional effect is observed with the addition of
IL-12 to the IL-2 culture. Thus, while these cytokines
promote Th1 cell differentiation of naive CD4CT cells,
they augment the Th1-like functions of NT cells.
Changes in cell phenotype following incubation with
IL-12 demonstrate the potential of the cytokine micro-
environment to influence the phenotypic profiles of
lymphocyte subpopulations in liver. The presence of
IL-12 may create an environment in the healthy liver
that influences the accumulation of CD8CT cells,
double positive CD4CCD8CT cells and NT cells, all
of which are known to have potent cytotoxic activities.
This inflammatory environment suggests a role for the
liver in immunity against tumours and the elevated
levels of IL-12 in tumour bearing compared to histo-
logically normal liver support this theory. However,
neither NT nor CD8CT cells are expanded in tumour
bearing compared to normal liver. Norris et al. [36]
showed no difference in the cytolytic function of these
populations in tumour bearing compared to normal
liver tissue, suggesting that natural T cells have not ac-
quired increased anti-tumour activity as a result of IL-12
in vivo. Therefore, the presence of metastases in those
livers containing high levels of IL-12 may be due to
an insufficient IL-12 response, or to a breakdown in the
IL-12/NT/CD8/IFN-g pathway. Surprisingly, IL-2 was
not elevated in tumour bearing liver tissue. This lack of
IL-2, rather than a defect in IL-12, may be responsible
for insufficient expansion/activation of tumour specific
cytotoxic T lymphocytes. Undoubtedly, it is the balance
and interplay between all cytokines and lymphocytes in
the liver that will ultimately determine the outcome of
the anti-tumour response.
4. Materials and methods
4.1. Tissue specimens
Normal liver tissue (100e200 mg) was obtained from
donor organs at the time of transplantation (n ¼ 13).
Donor organs were extensively perfused with University
of Wisconsin solution prior to obtaining the biopsy.
279A.M. Kelly et al. / Cytokine 25 (2004) 273e282Fig. 6. Expressions of CD8 and CD56 on hepatic T cells (CD3C) from normal and tumour bearing liver. Two thirds of CD3C cells from normal liver
co-express CD8. While the level in tumour bearing liver is more variable, there is no significant difference demonstrated (A). Flow cytometric
histogram analysis showing CD8 expression on CD3C hepatic cells from normal and tumour bearing liver. The dotted line represents the isotyped
matched control antibody (B). CD56 is co-expressed on hepatic CD3C cells at a median value of 20% in both normal and tumour bearing liver
(C and D).Wedge biopsies were obtained from tumour bearing
liver at the time of resection for colorectal metastases
(n ¼ 9). Resected tissue was washed three times in
Hanks Balanced Salt Solution (HBSS) to remove
residual blood. Hepatic lymphocytes were extracted
for flow cytometry by a combination of mechanical and
enzymatic disruption as described previously [37].
Whole liver tissue was immediately snap frozen in liquid
nitrogen for estimation of cytokine protein.Peripheral blood was obtained from volunteer con-
trols. Peripheral blood mononuclear cells (PBMCs) were
prepared by density gradient centrifugation (Lympho-
prep, Nycomed, Oslo, Norway). These cells were then
used for culture or for the preparation of protein
extracts.
The Ethics and Medical Research Committee at St.
Vincent’s University Hospital, Dublin, granted approval
for the study.
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Frozen liver samples were powdered using the Braun
Mikrodismembrator (Braun Apparate, Melsungen,
Germany). Protein was extracted from powdered tissue
using 300 ml of lysis buffer (1% Igepal, 0.5% deoxy-
cholic acid, 0.1% SDS in PBS) to which protease
inhibitors (10 ml/ml PMSF [phenylmethylsulphonyl-
flouride, dissolved in isopropanol], 3 ml/ml Aprotinin)
had been added. All reagents for the extraction of
protein were supplied by Sigma Aldrich, Ireland. The
tissue powder was homogenised in the lysis buffer by
passing several times through a 200 ml pipette tip. The
homogenate was then incubated on ice for 30 min,
followed by centrifugation at 10,000g for 10 min at
4 (C. The supernatant was harvested and total protein
was quantified using a bincinconic acid (BCA) protein
assay kit (Pierce, Rockford, IL, USA). The lysates were
stored at 80 (C. PBMC preparations (n ¼ 3) at
a concentration of 2!106=ml were stimulated for 6 h
using 10 ng/ml phorbol-12-myristate acetate (PMA) and
1 mg/ml ionomycin, in the presence of Brefeldin A
(10 mg/ml). Unstimulated cells were used as controls.
Following stimulation, the cells were pelleted and the
supernatant discarded. Protein was subsequently ex-
tracted from the cell pellets in the same manner as
described above for hepatic tissue.
4.3. Quantification of IL-12/IL-2 protein
A sandwich enzyme linked immunosorbent assay
(ELISA) suitable for use with hepatic tissue was
developed to measure cytokine protein levels in liver
and blood protein extracts. ELISA antibody pairs for
the detection of cytokine protein were obtained from
R&D Systems (Oxon, UK). The IL-12 capture and
detection antibodies were used at concentrations of
4 mg/ml and 250 ng/ml, respectively, and the IL-2
capture and detection antibodies were used at concen-
trations of 4 mg/ml and 100 ng/ml, respectively. Re-
combinant human IL-12 and IL-2 (R&D Systems) were
used to create a standard curve (range 0e1000 pg/ml).
The assay was performed as per the manufacturer’s
instructions. Samples and standards were assayed in
triplicate. A significant problem encountered in the use
of hepatic tissue is the non-specific binding of sample to
the plates and the contribution of endogenous alkaline
phosphatase and biotin to the signal generated. In order
to control for this, isotype matched IgG control anti-
body (Dako, Cambridge, UK) was used instead of
capture antibody at the same concentration (4 mg/ml)
for each of the samples examined, to control for the
background signal generated by the complex mix of hep-
atic tissue proteins [38]. The optical density was deter-
mined at 410 nm using a spectrophotometer (Dynatech,Guernsey, Channel Islands). The readings obtained
from the control wells were subtracted from the readings
obtained for the corresponding samples. The concen-
tration of cytokine protein in the unknown samples was
calculated against the standard curve and expressed as
pg/100 mg protein. The detection limit of the assays
under these conditions was determined as 15.6 pg/ml.
4.4. Localisation of IL-12 protein expression
in hepatic tissue
Sections (7 mm) were cut from frozen blocks of
hepatic tissue embedded in OCT, placed on glass slides
coated with 2% 3-amino-propyl-triethoxy-saline in
acetone (APES, Sigma Aldrich) and dried overnight at
room temperature. Immunoperoxidase staining of sec-
tions was carried out using the Vectastain Elite ABC
Kit (Vector Laboratories) according to the manufactur-
er’s guidelines. The primary antibody used was a mono-
clonal anti-IL-12 (R&D systems, MAB 219, 20 mg/ml).
IgG control antibody (Dako, Cambridge, UK, 20 mg/ml)
was used in place of the primary antibody as a neg-
ative control. The HRPesubstrate (diaminobenzi-
dine tetrahydrochloride, DAB, Sigma Aldrich) reaction
was allowed to proceed for 7 min and sections were
counterstained for 30 s in Mayer’s haemotoxylin
(BDH).
4.5. In vitro cell culture
PBMCs from nine healthy volunteers were cultured
at a concentration of 0:5!106=ml in 12 well plates
(Becton-Dickinson, Oxford, UK) coated with anti-
human CD3 antibody (5 mg/ml in 0.1 M Na2HPO4,
pH 9 [Pharmingen, San Diego, CA, USA]). Human
recombinant IL-2 alone (50 units/ml [Sigma Aldrich]) or
IL-2 in combination with human recombinant IL-12
(0.5 ng/ml [R&D Systems]) was added to the wells every
three days. Cells were restimulated with anti-CD3 every
seven days. Cells were harvested after 21 days culture.
Cells were counted by staining with ethidium bromide
and acridine orange.
4.6. Phenotypic analysis of cells
Monoclonal antibodies (mAb) specific for human
CD3, CD4, CD8, CD56, CD161, CD57, CD94, gdTCR,
abTCR, were obtained from Becton-Dickinson (Oxford,
UK). Cells surface expression of lymphocyte antigens on
peripheral blood cells and hepatic lymphocytes was
examined by mAb staining and analysis by three colour
flow cytometry (FACScan, Becton-Dickinson), before
and after culture.
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following culture
PBMCs from five healthy volunteers were cultured at
a concentration of 0:5!106=ml in 25 cm2 flasks (Corn-
ing, Cambridge, MA, USA) with IL-12, IL-2 and
a combination of IL-2 and IL-12 at the same concen-
trations as used above for 72 h. Cells cultured in
medium alone served as controls. Following culture,
PBMCs were stimulated for 4 h by CD3 crosslinking
using anti-human CD3 antibody (Pharmingen, San
Diego, CA, USA) in the presence of Brefeldin A
(10 mg/ml; Sigma, Poole, UK) for 4 h at 37 (C in 5%
CO2. This results in the accumulation of cytokine
proteins in the rough endoplasmic reticulum. To
determine levels of spontaneous cytokine production,
unstimulated cells (i.e. no anti-CD3) were simultaneously
incubated under the same conditions in the presence of
Brefeldin A. Cells surface expression of lymphocyte
antigens CD3, CD56 and intracellular cytokine expres-
sion of IFN-g and IL-4 was examined by mAb staining
and analysis by three colour flow cytometry (FACScan,
Becton-Dickinson).
4.8. Statistics
Differences between groups were assessed using
ManneWhitney U. A p value of !0.05 was taken as
significant.
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